Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology · 2026-07 · 183 (14) · 3970-3991
DOI: 10.1111/bph.17370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 28.10.2024. Verfasst von Laith Alexander und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Hauptthemen laut MEDLINE: Hallucinogens, Major Depressive Disorder, Antidepressive Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, National Institute for Health Research (NIHR) Biomedical Research Centre, National Institute for Health Research (NIHR).
Abstract (Originalsprache)
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood. For example, key questions such as whether antidepressant and psychedelic effects involve related or independent mechanisms are unresolved. Preclinical studies in relevant animal models are key to understanding the pharmacology of psychedelics and translating these findings to explain efficacy and safety in patients. Understanding the mechanisms of action associated with the behavioural effects of psychedelic drugs can also support the identification of novel drug targets and more effective treatments. Here we review the behavioural approaches currently used to quantify the psychedelic and antidepressant effects of psychedelic drugs. We discuss conceptual and methodological issues, the importance of using clinically relevant doses and the need to consider possible sex differences in preclinical psychedelic studies. LINKED ARTICLES This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- South London and the Maudsley NHS Foundation Trust, London, UK.
- School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.
ORCID-Profile: Emma S J Robinson
Förderung
- Biotechnology and Biological Sciences Research Council
- National Institute for Health Research (NIHR) Biomedical Research Centre
- National Institute for Health Research (NIHR)
- Wellcome Trust
- NIHR Academic Clinical Fellowship
- National Institute for Health and Care Research
- NIHR Cambridge Biomedical Research Centre
Zitieren
APA
Alexander, L., Anderson, D., Baxter, L., Claydon, M., Rucker, J., & Robinson, E. S. J. (2026). Preclinical models for evaluating psychedelics in the treatment of major depressive disorder. British Journal of Pharmacology, 183(14), 3970-3991. https://doi.org/10.1111/bph.17370
Vancouver
Alexander L, Anderson D, Baxter L, Claydon M, Rucker J, Robinson ESJ. Preclinical models for evaluating psychedelics in the treatment of major depressive disorder. British Journal of Pharmacology. 2026;183(14):3970-3991. doi:10.1111/bph.17370
BibTeX
@article{Alexander2026,
author = {Alexander, Laith and Anderson, Dasha and Baxter, Luke and Claydon, Matthew and Rucker, James and Robinson, Emma S J},
title = {Preclinical models for evaluating psychedelics in the treatment of major depressive disorder},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {14},
pages = {3970--3991},
doi = {10.1111/bph.17370}
}
EUVIMED